



Received on 12 January, 2018; received in revised form, 05 February, 2018; accepted, 13 February, 2018; published 01 June, 2018

## XANTHINE OXIDASE INHIBITORY ACTIVITY OF EXTRACTS PREPARED FROM *JUNIPERUS PHOENICEA*

Amira Mansour<sup>\*1</sup>, Yazid Foudil-Cherif<sup>2</sup>, Orsolya Orbán-Gyapai<sup>2</sup> and Ouahiba Belfadel<sup>2</sup>

USTHB, University of Sciences and Technology Houari Boumediene<sup>1</sup>, Faculty of Chemistry, BP 32 El-Alia, Bab-Ezzouar, 16111 Algiers, Algeria.

Centre of Research in Physical and Chemical Analysis (CRAPC)<sup>2</sup>, BP 384-Bou-Ismaïl-RP 42004, Tipaza, Algeria.

### Keywords:

*Juniperus phoenicea*,  
Xanthine Oxidase inhibition,  
Amentoflavone, Catechin, Gout

### Correspondence to Author: Amira Mansour

USTHB, University of Sciences and  
Technology Houari Boumediene,  
Faculty of Chemistry, BP 32 El-Alia,  
Bab-Ezzouar, 16111 Algiers, Algeria.

E-mail: mansour.amira13@yahoo.com

**ABSTRACT:** The inhibitory effect of *Juniperus phoenicea* leaves extracts on Xanthine Oxidase activity was evaluated spectrophotometrically at 290 nm. Extracts of *Juniperus phoenicea* showed a potent XO inhibitory activity. In order to isolate the active compounds, an *in vitro* bio-guided fractionation was undertaken by preparative chromatographic techniques. Fractions 2, 3 and 6 of ethyl acetate extract demonstrated substantial XO inhibitory activity (>80% inhibition) at 400 µg/mL. The highest inhibitory effect was obtained for the fraction 3 (87.8%). The major constituents amentoflavone (1) and catechin (2) isolated from the fraction 3 were identified by extensive spectroscopic studies including 1D and 2D NMR experiments. These two compounds have no inhibitory effect on xanthine oxidase, it is deduced that the XO activity of the fraction 3, was due either to a minor bioactive compound or possible synergisms. However this study showed that the tested plant species is potential source of natural XO inhibitors that can be developed, upon further investigation, for treatment of gout and other XO-related disorders.

**INTRODUCTION:** A common disease such as inflammation and related disorders are selected for our study and the primary target for treating these disorders includes the enzyme called xanthine oxidase (XO). The over-activity of this enzyme causes a disease called gout<sup>1</sup> and oxidative stress, which is characteristic for many vascular disease states<sup>2</sup> by generating superoxide anions. Gout is one of the most common metabolic disorders that affect humans.

It is characterized by marked hyperuricemia, leading to the deposition of urate monohydrate crystals in the joint and kidney, leading to gouty arthritis and uric acid nephrolithiasis.

The deposition of needle-shaped monosodium urate (UMS) crystals in the synovial fluid of the main joints produces acute, extremely painful arthritis with repeated attacks of gout<sup>3</sup>. The treatment of gout involves increasing the excretion of uric acid or reducing its production. Inhibitors of xanthine oxidase (XOI) are very useful<sup>4</sup> because they reduce both vascular oxidative stress and circulating levels of uric acid and they have minor side effects compared to uricosuric and anti-inflammatory agents. Allopurinol, widely used for the treatment of hyperuricemia and gout<sup>5</sup> have



many side effects such as hypersensitivity syndrome, Stevens-Johnson syndrome and renal toxicity<sup>6</sup>. So, finding new XOI would be beneficial not only for treating gout but also for combating various other diseases<sup>7,8</sup>.

Certain active constituents present in crude plant extracts like flavonoids and polyphenolic compounds have been reported to possess XOI<sup>9,10,11</sup>. These findings have opened the possibility of isolation of new natural compounds, which can be potent inhibitors of XO, and led to the growing interest in the investigation of medicinal plants.

In this study, the medicinal plant *Juniperus phoenicea* was selected for its XOI activity by its ethnomedical use in the treatment of inflammatory and rheumatic diseases.

*Juniperus phoenicea* called "Araar" in Arabic, is a tree or shrub up to 8 meters tall. This species extends from the Mediterranean region, occurring in southern Europe, western Asia and North Africa, also in eastern Portugal until in Turkey and Egypt, it extends from the Canary Islands to Saudi Arabia and Jordan, but is more common in the western part of the Mediterranean regions<sup>12,13</sup>.

Previous phytochemical studies of *Juniperus phoenicea* revealed that diterpenes are the main secondary metabolites of the plant<sup>14,15,16</sup>. Numerous biflavonoids including amentoflavone, robustaflavone, hinokiflavone, cupressuflavone and mono-O-methyl hinokiflavone were isolated from the leaf extract of *Juniperus phoenicea*<sup>17</sup>. Flavonoids<sup>12</sup>, phenylpropanoids<sup>18,19,20</sup>, and furanones<sup>21,22</sup> were also isolated from the plant. In the present studies in order to find new natural compounds, which can be potent inhibitors of XO we preceded to an Activity-guided phytochemical investigations of *Juniperus phoenicea*.

## MATERIALS AND METHODS:

**Chemicals:** Analytical grade n-butanol (n-BuOH), ethyl acetate, chloroform and methanol (MeOH) employed for extraction isolation procedures were obtained from Merck, Methanol deuterated (CD<sub>3</sub>OD) and xanthine powder were purchased from Sigma-Aldrich Co.

**General Experimental Procedures:** Column Chromatography was performed over Silica gel

(63-200)  $\mu\text{m}$ , (Merck, Darmstadt, Germany). Thin-layer chromatography (TLC) analysis was performed with precoated silica gel 60 F254 plates (Merck, Darmstadt, Germany), and the spray reagent cerium sulfate (saturated solution in dilute H<sub>2</sub>SO<sub>4</sub>) and UV (Shimadzu UV-1601, 254 and 366 nm) were used for the spot visualization. Preparative TLC was performed with precoated silica gel 60 F254 aluminium sheets (20  $\times$  20 cm, Merck, Darmstadt, Germany). The absorbance of XO-induced uric acid production from xanthine was measured at 290 nm, using the plate reader FluoSTAR OPTIMA (BMG LABTECH). A Bruker DRX-600 NMR spectrometer, operating at 599.19 MHz for <sup>1</sup>H and 150.858 MHz for <sup>13</sup>C, using the WINXNMR software package, was used for NMR experiments in CD<sub>3</sub>OD.

**Plant Material:** Aerial parts of *Juniperus phoenicea* were collected in from Tipaza area, located in north Algeria. A voucher specimen has been deposited in the Department of Chemistry, Algiers University.

**Extraction and Isolation:** Air-dried and coarsely powdered (1000g) leaves were macerated at room temperature with MeOH–H<sub>2</sub>O (80:20, v/v) for 24 h, and the operation was repeated 3 times. After filtration, the filtrate was concentrated (methanol extract) and dissolved in H<sub>2</sub>O (400 ml). The resulting solution was extracted successively with chloroform, EtOAc and n-butanol. The organic phases were concentrated in vacuo at room temperature to obtain the following extracts: Chloroform (1.73g), EtOAc (4.42 g) and n-butanol (22.8 g).

4 g of the EtOAc extract was fractionated over silica gel column using chloroform gradually enriched with ethyl acetate as eluent. Fractions were collected, and combined to 7 major fractions (F1-F7) based on TLC pattern. Fraction 3 was submitted to preparative TLC using as solvent a mixture of MeOH / H<sub>2</sub>O (8.5:1.5), to give two major constituents: amentoflavone (1) (5 mg) and catechin (2) (20 mg).

**Xanthine Oxidase Assay:** The method is based on a modified protocol of Sigma<sup>23</sup>. Spectrophotometric determination of XO activity is based on measuring uric acid production (absorbance)

from xanthine or hypoxanthine substrate at 290 nm for 3 min in a 96-well plate, using the plate reader FluoSTAR OPTIMA. The XO inhibitory effect was determined *via* the decreased production of uric acid. Reagents were 50 mM potassium phosphate buffer, pH 7.5 with 1M KOH, 0.15 mM xanthine solution (pH 7.5), and XO solution (0.2 units/mL). XO, isolated from bovine milk (lyophilized powder). The different extracts (12 mg/mL) were prepared in dimethyl sulfoxide (DMSO). For enzyme activity control, the final reaction mixture was made with 100  $\mu$ L of xanthine, 150  $\mu$ L of buffer and 50  $\mu$ L of XO in a 300  $\mu$ L well. The reaction mixture for inhibition comprised 100  $\mu$ L of xanthine, 140  $\mu$ L of buffer, 10  $\mu$ L of sample and 50  $\mu$ L of XO. Allopurinol served as positive control. All the experiments were conducted in triplicate. The reaction was initiated by the automatic addition of 0.050 mL of XO solution to a final concentration of 0.006 units/mL.

**RESULTS AND DISCUSSION:** The XO activity of extracts was calculated as % xanthine oxidase inhibition activity =  $1 - (\text{XOIs} / \text{XOIo}) \times 100 \%$ , where XOIs is enzyme activity with test sample and XOIo is enzyme activity without sample. The XO activity of extracts and fractions were summarized in **Table 1**.

**TABLE 1: PERCENTAGE OF DPPH RADICAL SCAVENGING ACTIVITY AND XANTHINE OXIDASE INHIBITORY ACTIVITY**

Samples (400 $\mu$ g/mL)	XOI Activity (% $\pm$ SD)
Methanol extract	42.12 $\pm$ 3.2
n-butanol extract	70.7 $\pm$ 8.4
Ethyl acetate extract	70.2 $\pm$ 4.7
F1	58.4 $\pm$ 8.2
F2	81.5 $\pm$ 2.3
F3	87.8 $\pm$ 4.5
F4	75.1 $\pm$ 1.3
F5	73.5 $\pm$ 1.6
F6	85.6 $\pm$ 4.2
F7	70.7 $\pm$ 6.5

At 400  $\mu$ g/mL, all of the investigated extracts displayed significant XO inhibitory activities. Fractions of ethyl acetate extract demonstrated substantial XO inhibitory activity ( $\geq 50\%$  inhibition), among them F2, F3 and F6 exhibited  $>80\%$  inhibitory effect. The most potent inhibitory effect was obtained for the fraction 3 **Table 1**, hence we chose it to continue the separation of our extract in order to find the compounds responsible for this inhibitory activity (XOI).

The major constituents of this fraction were identified as a bioflavonoid amentoflavone (1) and a flavanol catechin (2) on the basis of spectral evidences and comparison of spectral data with literature value<sup>17, 24</sup>. The presence of compounds 1 and 2 in *Juniperus phoenicea* was already mentioned<sup>17</sup>.

Phenolic and flavonoid compounds are reported to possess XO activities. Flavonoids that selected as potential XO inhibitor should consists either hydroxyl group at C-5 and C-7, or double bond between C-2 and C-3<sup>25, 26</sup>. According to Nagao et al, lower inhibitory activities among some flavonoids are due to substitution of hydroxyl groups at C-3 and C-7 by glycoside or methyl group<sup>26</sup> and some flavonoids that showed minimal or no XO activity are such as catechin, non-planar flavones and isoflavones<sup>26</sup>. In these studies, compounds 1 and 2 do not possess XO activity, we can deduce that the activity of fraction 3 was due either to a minor bioactive constituent or possible synergisms between polyphenols present in the fraction.

**CONCLUSION:** These studies revealed the potential of *Juniperus phoenicea* leaves to inhibit xanthine oxidase which therefore may have a positive impact on the prevention of disease caused by increased activity of XO. It is suggested that further purification such as silica gel vacuum chromatography and HPLC of fractions 2, 3, and 6 shall be carried out to identify a potential chemical entity for clinical use in the prevention and treatment of gout and related inflammatory disorders. Furthermore, *in vivo* XO activity assay can be done to further prove the antigout property of this medicinal plant.

**ACKNOWLEDGEMENT:** Nil

**CONFLICT OF INTEREST:** Nil

**REFERENCES:**

- Burke A, Smyth E and FitzGerald GA: Analgesic-antipyretic agents; pharmacotherapy of gout in The Pharmacological Basis of Therapeutics, Brunton LL, Lazo JS, and Parker KL, Eds, McGraw-Hill Medical Publishing Division, New York, NY, USA, 11<sup>th</sup> Edition, 2006; 706-710.
- Nieto FJ, Iribarren C, Gross MD, Comstock GW and Cutler RG: Uric acid and serum antioxidant capacity: a reaction to atherosclerosis. *Atherosclerosis* 2000; 148(1): 131-139.

3. Choi HK, Mount DB, and Reginato AM: Pathogenesis of gout. *Annals of Internal Medicine* 2005; 143(7): 499-516.
4. Umamaheswari M, AsokKumar K, Somasundaram A, Sivashanmugam T, Subhadradevi V, and Ravi TK: Xanthine oxidase inhibitory activity of some Indian medical plants. *Journal of Ethnopharmacology* 2007; 109(3): 547-551.
5. Ngoc TM, Khoi NM, Ha DT et al.: Xanthine oxidase inhibitory activity of constituents of *Cinnamomum cassia* twigs. *Bioorganic and Medicinal Chemistry Letters* 2012; 22(14): 4625-4628.
6. Pacher P, Nivorozhkin A and Szabo C: Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. *Pharmacol Rev* 2006; 58: 87-114.
7. Nguyen MTT, Awale S, Tezuka Y, Le Tran Q and Kadota S: Xanthine oxidase inhibitors from the heartwood of Vietnamese *Caesalpiniasappan*. *Chemical and Pharmaceutical Bulletin* 2005; 53(8): 984-988
8. Higgins P, Ferguson LD, and Walters MR: Xanthine oxidase inhibition for the treatment of stroke disease: a novel therapeutic approach. *Expert Review of Cardiovascular Therapy* 2011; 9(4): 399-401.
9. Azmi SMN, Jamal P and Amid A: Xanthine oxidase inhibitory activity from potential Malaysian medicinal plant as remedies for gout. *Int Food Res J* 2012; 19(1):159-165.
10. Costantino L, Albasini A, Rastelli G and Benvenuti S: Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase. *Planta Med* 1992; 58: 342-344.
11. Nana FW, Hilou A, Millogo JF and Nacoulma OG: Phytochemical Composition, Antioxidant and Xanthine Oxidase Inhibitory Activities of *Amaranthus cruentus* L. and *Amaranthus hybridus* L. Extracts. *Pharmaceuticals* 2012; 5: 613-628.
12. Maatooq GT, El-Sharkawy SH, Afifi MS and Rosazza JPN: Flavonoids from two Cupressaceae plants. *Nat. Prod. Sci* 1998; 4: 9-14.
13. Derwich E, Z.Benziane TR, Senhadji O and Touzani M: A comparative study of the chemical composition of the leaves volatile oil of *Juniperus phoenicea* and *Juniperus oxycedrus*. *Middl-East J.Res* 2010a; 5(5): 416-424.
14. Muhammad I, Mossa JS and El-Feraly FS: Antibacterial diterpenes from the leaves and seeds of *Juniperus excelsa*. *Phytother. Res* 1992; 6: 261-264.
15. Mossa JS, Muhammad I, El-Feraly FS and Hufford CD: 12- Dihydroxyabieta- 8, 11, 13- Triene-1-one and other constituents From *Juniperus excelsa* Leaves. *Phytochemistry* 1992 (3b); 31: 2789-2863.
16. Muhammad I, Mossa JS, Al-Yahya MA, Ramadan AF and El-Feraly FS: Further antibacterial diterpenes from the bark and leaves of *Juniperus procera* Hochst. exEndl. *Phytother. Res* 1995; 9: 584-588.
17. Fatma W, Taufeeq HM, Shaida WA and Rahman W: Biflavonoids from *Juniperus macropoda* Boiss and *Juniperus phoenicea* Linn. (Cupressaceae). *Indian J. Chem. B Org* 1979; 17: 193-194.
18. Hussein SAM, Merfort I and Nawwar MAM: Lignans and other phenylpropanoids from leaves of *Juniperus phoenicea*. *J.S.C.S* 2003; 7: 105-110.
19. Comte G, Chulia AJ, Vercauteren J and Allais DP: Phenyl propane glycosides from *Juniperus phoenicea*. *Planta Med* 1996c; 62: 88-89.
20. Comte G, Vercauteren J, Chulia AJ, Allais DP and Delage C: Phenyl propanoids from leaves of *Juniperus phoenicea*. *Phytochemistry* 1997; 45: 1679-1682.
21. Comte G, Allais DP, Chulia AJ, Vercauteren J and Bosso C: Phoenicoside, the first natural bisfuranone propane derivative from *Juniperus phoenicea* L. *Tetrahedron Lett* 1996a; 37: 2955-2958.
22. Comte G, Allais DP, Chulia AJ, Vercauteren J and Delage C: Two furanone glucoside derivatives from *Juniperus phoenicea*. *Phytochemistry* 1996b; 41: 1329-1332.
23. Orbán-Gyapai O, Lajter I, Hohmann J, Jakab G and Vasas A: Xanthine Oxidase Inhibitory Activity of Extracts Prepared from Polygonaceae Species. *Phytother. Res.* 2015; 29: 459-465.
24. Ennajar M, Bouajila J, Lebrihi A, Mathieu F, Abderraba M, Raies A and Romdhane M: Chemical composition and antimicrobial and antioxidant activities of essential oils and various extracts of *Juniperus phoenicea* L. (Cupressaceae). *J. Food Sci.* 2009; 74: M364-M371.
25. Ng LY, Ang YK, Khoo HE and Yim HS: Influence of Different Extractions on Antioxidant Properties of *Carica papaya* Peel and Seed. *Research Journal of Phytochemistry* 2012; 6:61-74.
26. Nagao A, Seki M and Kobayashi H: Inhibition of xanthineoxidase by flavonoids. *BiosciBiotechnolBioche* 1999; 63(10): 1787-1790.

**How to cite this article:**

Mansour A, Foudil-Cherif Y, Orbán-Gyapai O and Belfadel O: Xanthine oxidase inhibitory activity of extracts prepared from *Juniperus phoenicea*. *Int J Pharmacognosy* 2018; 5(6): 350-53. doi link: [http://dx.doi.org/10.13040/IJPSR.0975-8232.IJP.5\(6\).350-53](http://dx.doi.org/10.13040/IJPSR.0975-8232.IJP.5(6).350-53).

This Journal licensed under a Creative Commons Attribution-Non-commercial-Share Alike 3.0 Unported License.

This article can be downloaded to **ANDROID OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)